Enhanced Gene Delivery and Mechanism Studies with a Novel Series of Cationic Lipid Formulations
Overview
Affiliations
The application of cationic liposome reagents has advanced DNA and mRNA transfection research in vitro, and data are accumulating which show their utility for in vivo gene transfer. However, chemical structure-activity data leading to a better mechanistic understanding of their biological activity is still limited. Most of the cationic lipid reagents in use today for this application are formulated as liposomes containing two lipid species, a cationic amphiphile and a neutral phospholipid, typically dioleoylphosphatidylethanolamine (DOPE). The studies reported here examine the effects of some systematic chemical structural changes in both of these lipid components. Cationic and neutral phospholipids were formulated together as large multilamellar vesicles (MLV) or small sonicated unilamellar vesicles (SUV) in water, and each formulation was assayed quantitatively in 96-well microtiter plates under 64 different assay conditions using COS.7 cells and an RSV-beta-galactosidase expression plasmid. The cationic lipid molecules used for these studies were derived from a novel series of 2,3-dialkyloxypropyl quaternary ammonium compounds containing a hydroxyalkyl moiety on the quaternary amine. A homologous series of dioleylalkyl (C18:1) compounds containing increasing hydroxyalkyl chain lengths on the quaternary amine were synthesized, formulated with 50 mol % DOPE, and assayed for transfection activity. The order of efficacy was ethyl > propyl > butyl > pentyl > 2,3-dioleyloxypropyl-1-trimethyl ammonium bromide (DOTMA). DOTMA, which is commercially available under the trademark Lipofectin Reagent, lacks a hydroxyalkyl moiety on the quaternary amine. A homologous series of hydroxyethyl quaternary ammonium derivatives with different alkyl chain substitutions were synthesized, formulated with 50 mol % DOPE, and assayed in the transfection assay. The order of transfection efficacy was dimyristyl (di-C14:0) > dioleyl (di-C18:1) > dipalmityl (di-C16:0) > disteryl (di-C18:0). The addition of 100 microM chloroquine in the transfection experiment enhanced the activity of the dioleyl compound by 4-fold and decreased the activity of the dimyristyl compound by 70%. For each of the compounds and formulations examined in this report, large multilamellar vesicles (MLV; diameter 300-700 nm) were more active than small unilamellar vesicles (SUV; diameter 50-100 nm). The neutral phospholipid requirements for transfection activity in COS.7 cells with these cationic lipid molecules were examined.(ABSTRACT TRUNCATED AT 400 WORDS)
Transforming Medicine: Cutting-Edge Applications of Nanoscale Materials in Drug Delivery.
Tenchov R, Hughes K, Ganesan M, Iyer K, Ralhan K, Lotti Diaz L ACS Nano. 2025; 19(4):4011-4038.
PMID: 39823199 PMC: 11803921. DOI: 10.1021/acsnano.4c09566.
Boosting Lipofection Efficiency Through Enhanced Membrane Fusion Mechanisms.
Pavlov R, Akimov S, Dashinimaev E, Bashkirov P Int J Mol Sci. 2025; 25(24.
PMID: 39769303 PMC: 11677079. DOI: 10.3390/ijms252413540.
Mrksich K, Padilla M, Mitchell M Adv Drug Deliv Rev. 2024; 214:115446.
PMID: 39293650 PMC: 11900896. DOI: 10.1016/j.addr.2024.115446.
The 60-year evolution of lipid nanoparticles for nucleic acid delivery.
Cullis P, Felgner P Nat Rev Drug Discov. 2024; 23(9):709-722.
PMID: 38965378 DOI: 10.1038/s41573-024-00977-6.
Messenger RNA-Based Therapeutics and Vaccines: What's beyond COVID-19?.
Li D, Liu C, Li Y, Tenchov R, Sasso J, Zhang D ACS Pharmacol Transl Sci. 2023; 6(7):943-969.
PMID: 37470024 PMC: 10353067. DOI: 10.1021/acsptsci.3c00047.